Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience

Panovska Stavridis, Irina; Pivkova Veljanovska, Aleksandra; Ridova, Nevenka; Stojanoski, Zlate; CHadievski, Lazar; Trajkova, Sanja; Popova-Labacevska, Marija; Matevska-Geshkovska, Nadica; CHevrevska, Lidija; Georgievski, Borche; Dimovski, Aleksandar

doi:10.2478/prilozi-2020-0040

Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience

Journal

Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)

Date Issued

2020-12-08

Author(s)

Ridova, Nevenka

Popova-Labacevska, Marija

Matevska-Geshkovska, Nadica

DOI

10.2478/prilozi-2020-0040

Abstract

Minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) cases is a complex, multi-modality process and, though much of its clinical implications at different points are extensively studied, it remains even now a challenging area. It is a disease the biology of which governs the modality of MRD assessment; in patients harboring specific molecular targets, high sensitivity techniques can be applied. On the other hand, relapse is considered as the leading cause of treatment failure in AML patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT).